KD Pharma Group has acquired dsm-firmenich's Marine Lipids business, enhancing its position in the omega-3 market while enabling dsm-firmenich to become a co-shareholder.

Target Information

KD Pharma Group ("KD Pharma"), a prominent contract development and manufacturing organization (CDMO) specializing in pharmaceutical and nutritional lipids, has recently announced its acquisition of the Marine Lipids business from dsm-firmenich. This acquisition grants dsm-firmenich a minority stake in KD Pharma, allowing them to become co-shareholders alongside capiton Omega continuation fund vehicles and other minority investors. The deal anticipates closing in 2024, pending customary regulatory approvals.

The transaction encompasses dsm-firmenich’s fish oil omega-3 business, targeting the dietary supplement and pharmaceutical markets, along with production facilities located in Piura, Peru, and Mulgrave, Canada. This strategic acquisition aims to enhance KD Pharma’s capabilities in marine lipids, merging the respective strengths of both companies in the process.

Industry Overview in Peru and Canada

The marine lipids industry has been experiencing substantial growth, driven by the increasing consumer awareness of health and wellness benefits associated with omega-3 fatty acids. In Pe